Objective: Single-station N2 (Stage IIIA) non-small-cell lung cancer has been reported to have a relatively favorable prognosis after surgery. However, most previous studies examined surgical outcomes in N2 disease by pathologic nodal status but not by clinical nodal status. The objective of this study was to clarify the surgical outcomes in clinical single-station N2 nonsmall-cell lung cancer patients. Methods: A total of 125 consecutive patients with clinical single-station N2 non-small-cell lung cancer were treated in our institution between 1992 and 2008. Among them, 97 (78%) patients underwent thoracotomy, and were included in this retrospective study. We defined clinical single-station N2 node as a node measuring 1 -2 cm in a single mediastinal station observed on contrast-enhanced computed tomography. The median follow-up period was 5.9 years (range, 1.8 -12.6). Results: Eighty-eight (91%) patients underwent lung resection. Of them, 17 (19%) had true (pathologic) single-station N2 disease. Twenty-eight (32%) had pathologic multistation N2 and 43 (49%) had pN0 -1 disease with favorable prognoses. The overall survival of the clinical single-station N2/pathologic N2 patients after initial surgery was unsatisfactory with a 5-year overall survival of 23.6%, but their prognoses were heterogeneous. True single-station pathologic N2 status (hazard ratio ¼ 0.35, P ¼ 0.008) and negative subcarinal node status (hazard ratio ¼ 0.34, P ¼ 0.022) were independent favorable prognostic factors after initial resection for clinical single-station N2/ pathologic N2 patients. The patients with both factors revealed a relatively favorable 5-year overall survival of 43.8%. Conclusion: Clinical single-station N2 status does not always correspond with pathologic true N2 status. From a prognostic point of view, initial surgery for clinical single-station N2 patients is indicated if their true single-station N2 status and negative subcarinal involvement are preoperatively confirmed.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) of clinical N2 (cN2) Stage IIIA disease is considered to be an occult systemic disease with a significantly poor prognosis (1) . The survival of cN2 patients with pathologically confirmed N2 ( pN2) after surgery alone has been reported to be dismal ( 10 -15% of 5-year overall survival [OS] ) in previous series (2, 3) , and initial surgery is generally not indicated for cN2 patients, even if the tumor is technically resectable (1) . Many researchers have conducted clinical trials of induction chemotherapy or chemoradiotherapy (CRT) followed by surgery since the 1990s (4 -8) , but the role of surgery in the multimodality approach is still controversial. Selected N2 patients having downstaged N status or resectable lesion by lobectomy might have surgical indication after CRT (8) . However, definitive CRT is currently the recommended treatment of choice for cN2 disease, irrespective of resectability (1) . On the other hand, several researchers have demonstrated that minimal N2 disease, such as single-station N2 disease (N2 disease limited to a single mediastinal station), is a favorable prognostic indicator of resected pN2 disease (9 -15) . Therefore, the question arises as to whether patients with clinical single-station N2 (csN2) NSCLC benefit from initial complete resection. Most previous studies examined surgical outcomes of N2 disease by 'pathologic' nodal status but not by 'clinical' nodal status. The objectives of this study were to retrospectively clarify the outcome of csN2 NSCLC patients after initial surgery.
PATIENTS AND METHODS

STUDY POPULATION
This study was approved by the Institutional Review Board in June 2010, and written informed consent was waived. Patients' baseline characteristics, treatment modalities and treatment outcomes were obtained retrospectively from the medical records. We reviewed the clinical and pathologic records of NSCLC patients at our hospital between 1993 and 2008. Among them, there were 595 cN2 Stage IIIA patients. Our diagnostic criterion of cN2 has been the presence of enlarged (1 cm) mediastinal node on contrast-enhanced computed tomography (CT). A CONSORT diagram of these patients is shown in Fig. 1 . A total of 125 (21%, 125/595) patients had csN2 disease, which was defined as NSCLC with non-bulky (1 -2 cm) N2 node in a single mediastinal station on the Naruke's lymph node map on contrast-enhanced CT, and were enrolled in this study. The remaining 470 patients had multistation or bulky N2 disease, or poor performance status which precluded active treatment. Before treatment, all the patients underwent thorough staging examinations with chest roentgenography, chest and abdominal contrastenhanced CT, brain CT or magnetic resonance imaging and bone scintigraphy or positron emission tomography (PET). All diagnoses of csN2 were made based on contrast-enhanced chest CT scans. Although PET was performed in selected patients from 2002, csN2 status was determined by CT findings for all the patients in this series.
TREATMENT DECISION MAKING
The management of the csN2 patients was decided by the institutional cancer board, which consisted of thoracic (20) .
STATISTICAL ANALYSIS
Student's t-test and Pearson's x 2 test were used for comparison. The OS and recurrence-free survival (RFS) were calculated by applying the Kaplan -Meier method starting at the date of resection (initial surgery cases) or the first day of CRT (definitive CRT cases); the log-rank test was used to compare survival curves. The median follow-up period was 5.9 years (range, 1.8 -12.6). Multivariate analysis was performed using the Cox proportional hazards model to identify independent prognostic factors. All P values were two sided, and a P value of ,0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with the GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA, USA) software and the JMP version 8.02 (SAS Institute, Inc., Cary, NC, USA) software.
RESULTS
TREATMENT COURSES OF THE PATIENTS WITH CSN2 DISEASE Figure 1 shows treatment courses of the 125 csN2 patients. A total of 97 patients (78%) underwent primary thoracotomy without preoperative histologic examination of csN2 nodes, and the remaining 28 patients received mediastinoscopic (n ¼ 26) or thoracoscopic (n ¼ 2) biopsy of csN2 nodes. In 5 of the 28 patients, N2 disease was histologically not identified, and they subsequently underwent thoracotomy. Among the remaining 23 patients whose pN2 status (csN2/pN2) was confirmed by biopsy, 18 patients underwent definitive CRT and 3 underwent induction chemotherapy followed by surgery. Table 1 shows patient characteristics of csN2 patients who underwent initial surgery. Nine patients had unresectable disease (unresectable T4, n ¼ 3; pleural dissemination, n ¼ 6). Subsequently, 88 underwent lung resection. Pathologic examination revealed true (pathologic) N2 disease (csN2/pN2) in 45 (51%) patients. The remaining 43 (49%) patients had pN0 (csN2/pN0, n ¼ 31) or pN1 (csN2/pN1, n ¼ 12) disease. Among the 45 csN2/pN2 patients, true ( pathologic) singlestation N2 (csN2/psN2) was identified in 17 patients, and the remaining 28 patients had clinically undetected pathologic multistation N2 disease (csN2/pmN2). The positive predictive value of single-station N2 disease by contrast-enhanced CT was The survival of csN2 patients after initial surgery according to final pathologic N status is shown in Fig. 2A Table 2 . Locoregional and distant failures occurred almost equally. The treatment modalities for recurrence were CRT in 3 (9%), chemotherapy in 8 (25%) and local radiotherapy in 6 (19%), respectively. In this study, one patient received epidermal growth factor receptor tyrosine kinase inhibitor as an initial therapy for first recurrence.
PATIENT CHARACTERISTICS AND FINAL PATHOLOGIC N STATUS OF CSN2 PATIENTS AFTER INITIAL SURGERY
PROGNOSTIC FACTORS IN CSN2/PN2 PATIENTS AFTER INITIAL SURGERY
The results of univariate analysis by using the log-rank test are shown in Table 3 . True ( pathologic) single-station N2 status (csN2/psN2, P ¼ 0.024), number of metastatic nodes Table 4 ). The survival curves of csN2/pN2 patients after initial surgery according to the status of these two prognostic factors are shown in Fig. 3A and B. Patients with the two factors (psN2/#7-negative, n ¼ 11) revealed relatively favorable 5-year RFS and OS of 37.5 and 43.8%, respectively. In contrast, all patients without the two factors (pmN2/#7-positive, n ¼ 12) developed recurrence within 1.1 years and died within 2 years of initial surgery. The survival curves of the patients with one of these factors crossed over each other, but the patients with psN2 limited in #7 station (psN2/#7-positive) tended to show a slightly favorable survival compared with pmN2 without #7 involvement (5-year RFS and OS, psN2/#7-positive: 33.3 and 33.3%, pmN2/#7-negative: 25.0 and 25.0%, respectively).
DISCUSSION
In the current study, of the 88 csN2 patients who underwent initial surgery, true ( pathologic) N2 (csN2/pN2) status was identified in approximately half (51%) of the patients, while the remaining patients had pN0 -1 (csN2/pN0 -1) disease, with favorable prognoses. The positive predictive value of single-station N2 disease by contrast-enhanced CT was only 19% (17/88). CT scans still play a central role in lung cancer staging, but pooled data yielded a sensitivity of 57%, specificity of 82%, positive predictive value of 56% and negative predictive value of 83% (21). Yoshino et al. (22) recently analyzed the surgical outcomes of 800 NSCLC patients with On the other hand, the survival of the csN2 patients whose N2 was pathologically confirmed after initial surgery (csN2/ pN2 patients) was unsatisfactory. The 5-year RFS and OS were 22.3 and 23.6%, respectively. In the current study period, a total of 18 patients with the same N2 burden (csN2/ pN2) underwent CRT, a standard treatment modality especially in western countries. Their 5-year RFS and OS were 22.2 and 27.8%, respectively. This was a retrospective small study and we could not compare the survival results for csN2/pN2 patients after initial surgery and CRT. However, the current results imply that the western guideline recommending CRT for cN2/pN2 NSCLC also applies to csN2/pN2 disease. The The two prognostic factors for resected csN2/pN2 NSCLC patients, psN2 status and negative subcarinal station, have been reported as favorable prognostic factors for resected 'cN0 -1/ pN2' NSCLC patients in many studies (9 -14,23,24) . In the Japanese Lung Cancer Registry Study in 2004, psN2 status was also shown to be a significant favorable prognostic indicator in resected 436 'cN2/pN2' NSCLC patients (5-year OS, cN2/ psN2 35.8%, cN2/pmN2 22.0%, P ¼ 0.0053) (22) . Regnard et al. (23) analyzed the survival of 254 pN2 NSCLC patients and demonstrated that pN2 patients with negative subcarinal node had a 5-year OS of 34%. In the current study, both two factors were also important for 'csN2/pN2' patients after surgery. N2 disease without concomitant N1 involvement (skip N2) and smaller size of primary tumor (lower T-classification) have also been reported to be prognostic factors (12, 24) , but these were not shown to be statistically significant in the current study, possibly due to the small sample size.
Initial surgery may be beneficial to csN2/psN2 without subcarinal involvement, but such patients accounted for only in 13% (11/88) of the resected csN2 NSCLC patients in our cohort. Clinically undetectable pmN2 disease (csN2/pmN2) was observed in 32% (28/88). On the other hand, it is also notable that 49% (43/88) of the resected csN2 diseases were pN0 -1 diseases. Additional diagnostic modalities including PET combined with CT (PET -CT), mediastinoscopic biopsy or endobronchial ultrasound-guided (EBUS) biopsy are mandatory for csN2 diseases diagnosed by CT, in order to reduce overdiagnoses and select appropriate surgical csN2/pN2 candidates, #7-negative csN2/psN2 disease. PET -CT has been widely used as a non-invasive staging modality of NSCLC (21, 25) . Due to its high negative predictive value of over 90% (25) , when csN2 node detected on CT is negative on PET -CT, which suggests pN0 -1, initial surgical resection may be the treatment of choice. Also, when PET -CT reveals negative #7 station in csN2 patients, initial surgical resection may be justified. In the current series, six patients were diagnosed as csN2 not only by CT but also by PET-CT. Among them, five actually had psN2. In contrast, the positive predictive value of PET -CT scan is only 70% (25) . If other positive mediastinal nodes were depicted for csN2 patients on PET -CT, the exact N2 status (single or multistation) should be confirmed by biopsy. csN2 patients whose N2 status proved to multistation by biopsy should be indicated for definitive CRT or induction therapy followed by surgery. Although mediastinoscopic biopsy remains to be the gold standard of invasive staging, recent minimally invasive endoscopic techniques including EBUS transbronchial needle aspiration have been proved to replace mediastinoscopic biopsy because of the similar high performance reported in determining the true pathologic N status (26) and should be used more in clinical practice.
This study includes some limitations. First, this is a retrospective study based on a small cohort in a single institution. Secondly, csN2 patients were not randomly allocated to between initial surgery and other treatment modalities. The study population included selection bias, and we could not evaluate the significance of initial surgery for csN2 patients relative to CRT, a standard treatment modality especially in western countries. Due to these limitations, it may be inadequate to draw definite conclusions from our results. However, our results clearly indicated that true csN2 patients without subcarinal involvement among csN2 patients could achieve relatively long-term survival (5-year OS: 43.8%) by initial surgery. Nowadays, cisplatin-based adjuvant chemotherapy has been a standard of care for resected pN2 NSCLC patients. Further study should be conducted focusing on whether adjuvant chemotherapy produces further survival improvement for this csN2 population (#7-negative true csN2).
In conclusion, as this retrospective study showed that approximately one half of the csN2 NSCLC patients actually had pN0 -1 diseases, we should not exclude surgical resection as their treatment option based only on CT findings. However, the csN2/pN2 patients revealed heterogeneous outcomes after initial surgery in terms of their prognosis. Initial surgery is indicated for csN2/pN2 patients if the true single-station csN2/pN2 without subcarinal involvement is preoperatively confirmed.
